591 related articles for article (PubMed ID: 19189037)
21. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of osteoporosis (with the exception of hormone replacement and its derivates].
Lamy O; Mischler C; Krieg MA
Rev Med Suisse Romande; 2002 Aug; 122(8):389-93. PubMed ID: 12357732
[TBL] [Abstract][Full Text] [Related]
24. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
25. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
26. [Glucocorticoid-induced osteoporosis : treatment update].
Soen S
Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
28. Teriparatide for severe osteoporosis.
Cappuzzo KA; Delafuente JC
Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
[TBL] [Abstract][Full Text] [Related]
29. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
30. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
33. Bone-forming agents in the management of osteoporosis.
Neuprez A; Reginster JY
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
[TBL] [Abstract][Full Text] [Related]
34. The role of teriparatide in sequential and combination therapy of osteoporosis.
Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
36. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone as an anabolic therapy for women and men.
Bilezikian JP; Rubin MR; Finkelstein JS
J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
[TBL] [Abstract][Full Text] [Related]
38. Treatment of osteoporosis: all the questions we still cannot answer.
Laroche M
Am J Med; 2008 Sep; 121(9):744-7. PubMed ID: 18724959
[TBL] [Abstract][Full Text] [Related]
39. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
40. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]